Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Palvella Therapeutics

Palvella Therapeutics
Public Companies

Palvella Therapeutics Joins Russell 3000 and Russell 2000 Indexes

June 30, 2025June 30, 2025 - by Timothy Alexander

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has announced its inclusion in both the Russell 3000® Index and the Russell 2000® Index as part of the 2025 reconstitution of …

Palvella Therapeutics Joins Russell 3000 and Russell 2000 Indexes Read More

Palvella Therapeutics
Research

Palvella Therapeutics Announces Completion of Phase 3 SELVA Trial for QTORIN Rapamycin

June 24, 2025June 23, 2025 - by Timothy Alexander

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has successfully completed enrollment in the Phase 3 SELVA clinical trial of QTORINâ„¢ 3.9% rapamycin anhydrous gel, a potential breakthrough treatment for …

Palvella Therapeutics Announces Completion of Phase 3 SELVA Trial for QTORIN Rapamycin Read More
Palvella Therapeutics
Business

Palvella Therapeutics Secures New Patent for QTORINâ„¢ Rapamycin

June 18, 2025June 18, 2025 - by Timothy Alexander

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the issuance of U.S. patent No. 12,329,748 by the United States Patent and Trademark Office (USPTO), providing increased protection for its …

Palvella Therapeutics Secures New Patent for QTORINâ„¢ Rapamycin Read More

Palvella Therapeutics
Business

Palvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN Rapamycin

June 11, 2025June 10, 2025 - by Timothy Alexander

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has received the initial proceeds from a prestigious FDA Orphan Products Development grant to support its ongoing Phase 3 SELVA trial of …

Palvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN Rapamycin Read More
Palvella Therapeutics
Executives

Palvella Therapeutics Names Ashley Kline Chief Commercial Officer

May 29, 2025May 28, 2025 - by Timothy Alexander

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has announced the immediate appointment of Ashley Kline as Chief Commercial Officer. With a proven history of launching therapies for rare diseases, …

Palvella Therapeutics Names Ashley Kline Chief Commercial Officer Read More

Palvella Therapeutics
Finance

Palvella Therapeutics Reports Q1 2025 Financials and Clinical Progress

May 18, 2025May 17, 2025 - by Timothy Alexander

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has released its financial results for the first quarter of 2025, along with key updates from its clinical development programs for QTORINâ„¢ …

Palvella Therapeutics Reports Q1 2025 Financials and Clinical Progress Read More
Palvella Therapeutics
Finance

Palvella Therapeutics to Announce Q1 2025 Financial Results and Host Investor Call

May 11, 2025May 10, 2025 - by Timothy Alexander

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) will release its first quarter 2025 financial results on Thursday, May 15, 2025.

Palvella Therapeutics to Announce Q1 2025 Financial Results and Host Investor Call Read More

Palvella Therapeutics
Public Companies

Palvella Therapeutics to Ring Nasdaq Opening Bell

May 9, 2025May 8, 2025 - by Timothy Alexander

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) will mark a significant corporate milestone by ringing the opening bell at the Nasdaq Stock Market on Monday, May 12, 2025, in …

Palvella Therapeutics to Ring Nasdaq Opening Bell Read More
Palvella Therapeutics
Public Companies

Palvella Therapeutics to Present Key Findings on Lymphatic Malformations at Dermatology Conference

April 28, 2025April 27, 2025 - by Timothy Alexander

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced that an abstract presenting groundbreaking data on the prevalence and annual incidence of lymphatic malformations (LMs) in the U.S. has been …

Palvella Therapeutics to Present Key Findings on Lymphatic Malformations at Dermatology Conference Read More
Palvella Therapeutics
Business

Palvella Therapeutics Secures New U.S. Patent for QTORIN Rapamycin

April 23, 2025April 22, 2025 - by Timothy Alexander

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has secured its fifth U.S. patent for QTORINâ„¢ 3.9% rapamycin anhydrous gel, reinforcing its position in the development of treatments for rare …

Palvella Therapeutics Secures New U.S. Patent for QTORIN Rapamycin Read More

Posts pagination

1 2 3 Next

Trending News

  • Teens Busted After Dawn Dunkin’ Heist in Bear — Cash Stolen, All Four Arrested

  • HHS Reverses Clinton-Era Policy, Restricts Federal Benefits to U.S. Citizens

  • Runaway Truck Smashes Sinking Spring Business, Sparks Gas Leak — Police Seek Help to Track Driver

  • VA Expands Burial Benefits for Veterans Receiving Hospice Care at Home

  • Fugitive Husband Accused of Brutal Assault Captured After Weeks on the Run

Subscribe for Updates

Follow Us

  • Facebook
  • X
  • LinkedIn
  • Google
  • RSS Feed

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Arrested

Teens Busted After Dawn Dunkin’ Heist in Bear — Cash Stolen, All Four Arrested

July 14, 2025July 14, 2025

US Department of Health and Human Services (HHS)

HHS Reverses Clinton-Era Policy, Restricts Federal Benefits to U.S. Citizens

July 14, 2025July 13, 2025

Ryder truck

Runaway Truck Smashes Sinking Spring Business, Sparks Gas Leak — Police Seek Help to Track Driver

July 14, 2025July 14, 2025

Copyright © 2025 MyChesCo.